Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 18;13:17562872211022870. doi: 10.1177/17562872211022870

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — (a) Therapeutic pathway algorithm which addresses a possible therapeutic pathway for the selection of second-line treatment for renal cell carcinoma. Therapy selection after tyrosine kinase inhibitor (TKI) first-line treatment. (b) Therapeutic pathway algorithm which addresses a possible therapeutic pathway for the selection of second-line treatment for renal cell carcinoma. Therapy selection after combination of TKI and immune checkpoint inhibitor (IO-TKI) in first-line treatment. (c) Therapeutic pathway algorithm which addresses a possible therapeutic pathway for the selection of second-line treatment for renal cell carcinoma. Therapy selection after combination of immune checkpoint inhibitor (IO-IO) in first-line treatment.